Production of recombinant proteins by vaccinia virus in a microcarrier based mammalian cell perfusion bioreactor.

Printer-friendly versionPrinter-friendly versionPDF versionPDF version
TitleProduction of recombinant proteins by vaccinia virus in a microcarrier based mammalian cell perfusion bioreactor.
Publication TypeJournal Article
Year of Publication2005
AuthorsBleckwenn, NA, Golding, H, Bentley, WE, Shiloach, J
JournalBiotechnol Bioeng
Volume90
Issue6
Pagination663-74
Date Published2005 Jun 20
ISSN0006-3592
KeywordsBioreactors, Cell Culture Techniques, Feasibility Studies, HeLa Cells, HIV Envelope Protein gp120, Humans, Protein Engineering, Recombinant Proteins, Vaccinia virus, Viral Proteins, Virus Cultivation
Abstract

The HeLa cell-vaccinia virus expression system was evaluated for the production of recombinant proteins (enhanced green fluorescent protein (EGFP) and HIV envelope coat protein, gp120) using microcarriers in 1.5 L perfused bioreactor cultures. Perfusion was achieved by use of an alternating tangential flow device (ATF), increasing the length of the exponential phase by 50 h compared to batch culture and increasing the maximum cell density from 1.5x10(6) to 4.4x10(6) cell/mL. A seed train expansion method using cells harvested from microcarrier culture and reseeding onto fresh carriers was developed. EGFP was first used as a model protein to study process parameters affecting protein yield, specifically dissolved oxygen (DO) and temperature during the production phase. The highest level of EGFP, 12+/-1.5 microg/10(6) infected cells, was obtained at 50% DO and 31 degrees C. These setpoints were then used to produce glycoprotein, gp120, which was purified and deglycosylated, revealing a significant amount of N-linked glycosylation. Also, biological activity was assayed, resulting in an ID50 of 3.1 microg/mL, which is comparable to previous reports.

DOI10.1002/bit.20423
Alternate JournalBiotechnol. Bioeng.
PubMed ID15858791